Category: Products & Tech

OmniPod Logo

Insulet to Develop OmniPod Insulin Pump for Type 2 Diabetes

Insulet Corporation, the company behind the OmniPod tubeless Insulin Management System, announced it has entered into an agreement with Eli Lilly and Company according to which Insulet will develop a new version of the OmniPod insulin pump specifically designed to deliver Eli Lilly's Humulin R U-500 insulin,
0 Shares
OneTouch_VerioIQ

LifeScan Recalls OneTouch VerioIQ Blood Glucose Meters

Johnson & Johnson's LifeScan, Inc. is initiating a voluntary recall and replacement for all of its OneTouch VerioIQ blood glucose meters in the United States, effective immediately. LifeScan is recalling and replacing all OneTouch VerioIQ Meters because at extremely high blood glucose levels of 1024 mg/dL and above, the meter will not provide a warning that the blood glucose is extremely high and will shut off, thereby potentially leading to incorrect treatment and delaying proper treatment.
0 Shares
fda

FDA To Re-Evaluate Type 2 Diabetes Drugs Following New Research

The FDA is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis, or inflammation of the pancreas, and pre-cancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with a class of drugs called incretin mimetics.
0 Shares
Tandem Diabetes Care Logo

FDA Approves t:connect Diabetes Management Application for Use With Tandem’s t:slim Insulin Pump

The U.S. FDA cleared Tandem's t:connect Diabetes Management Application, the web-based data management companion to the t:slim Insulin Pump. The t:connect Application is a Mac and PC-compatible data management software application that provides t:slim pump users and their healthcare providers a fast, easy, and visual way to display data from the pump and supported blood glucose meters.
0 Shares
sanofi-logo

FDA to Review NDA for Lixisenatide, Sanofi’s New Type 2 Diabetes Therapy

The FDA has accepted Sanofi's New Drug Application (NDA) for lixisenatide, the first once-daily prandial GLP-1 receptor agonist for the treatment of adults with type 2 diabetes, for review. The acceptance of the lixisenatide NDA filing follows the February 1, 2013, European Commission approval of lixisenatide in the European Union.
0 Shares
sanofi-logo

Lyxumia, Sanofi’s Type 2 Diabetes Treatment, Approved in EU

The European Commission has granted Marketing Authorisation in Europe for Sanofi's new type 2 diabetes treatment, Lyxumia (lixisenatide). Lyxumia is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of patients with type 2 diabetes mellitus. GLP-1 is a naturally-occurring peptide hormone that is released within minutes after eating a meal.
0 Shares